Fast track to enter the Chinese market

Experienced partners

Since 2014, Dongcheng Pharmaceutical has entered the high-tech barrier and high growth nuclear medicine industry with a high starting point. Dongcheng Nuclear Medicine has successively acquired Chengdu Yunke Pharmaceutical, Shanghai Yitai Pharmaceutical, and GMS (China), completing the company's full industry chain layout from diagnostic nuclear medicine to therapeutic nuclear medicine. In 2017, Dongcheng Pharmaceutical acquired 100% equity of Nanjing Andike Positron Research and Development Co., Ltd., further establishing the company's leading position in the field of nuclear medicine in China and becoming an enterprise that can provide comprehensive nuclear medicine solutions in the Chinese market.

As one of the leading nuclear medical enterprises in China, the company has established a leading domestic network for the production and distribution of radioactive drugs; The products on sale have achieved full coverage of "screening diagnosis treatment"; Multiple innovative varieties under research are in the preclinical and clinical trial stages. The company has initially formed five major platforms: nuclide supply platform, drug incubation platform, transformation service platform, production and distribution platform, and diagnosis and treatment marketing platform. It has basically completed the layout of the entire nuclear medical industry chain from raw material supply, research and development, clinical transformation, production, and sales, and has built a complete Dongcheng Pharmaceutical nuclear medical ecosystem.